UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
FORM 8-K
|
|
|
|
CURRENT REPORT
|
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|
|
|
Date of Report (Date of earliest event reported): March 27, 2020
|
|
|
|
AIKIDO PHARMA INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
000-05576
|
52-0849320
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
One Rockefeller Plaza, 11th Floor, New York, NY
|
10020
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code: (703) 992-9325
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value
|
AIKI
|
The Nasdaq Capital Market
|
On March 27, 2020, AIkido Pharma Inc., a Delaware
corporation (the “Company”), issued a press release (the “Press Release”) announcing that the record date
and distribution date to the Company’s stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) will be deferred
because of the requirement that the shares be registered prior to distribution. AIkido will provide a record date and distribution
date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update
to stockholders in two weeks on the status of this matter.
A copy of the Press Release is attached hereto
as Exhibit 99.1 and is incorporated by reference in this Current Report.
Item 9.01. Financial Statements and Exhibits
d) Exhibits.
The exhibit listed in the
following Exhibit Index is filed as part of this Current Report on Form 8-K.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press Release, dated March 27, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AIKIDO PHARMA INC.
|
|
|
|
|
|
By:
|
/s/ Anthony Hayes
|
|
|
Name:
Title:
|
Anthony Hayes
Chief Executive Officer
|
Dated: March 27, 2020
Exhibit 99.1
AIkido Pharma Inc. Provides Update on Timing
of Record Date and Anticipated Distribution Date for Dividend Distribution
NEW YORK, NY
March 27, 2020 /PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido”
or the “Company”) today announced that the record date and distribution date to our stockholders of shares of Hoth
Therapeutics, Inc. (“Hoth”) will be deferred because of the requirement that the shares be registered prior to distribution.
AIkido will provide a record date and distribution date for the distribution of the shares promptly once the registration statement
is declared effective and will issue an update to shareholders in two weeks on the status of this matter.
About AIkido
AIkido was initially formed in 1967 and is
a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists
of patented technology from leading universities and researchers and we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of
Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might,"
"will," "should," "believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release. These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's
filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially
different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information,
future events or otherwise, except as required by law.
Contact:
|
Investor Relations:
|
|
Hayden IR
|
|
|
|
Brett Maas, Managing Partner
|
|
|
|
Phone: (646) 536-7331
|
|
|
|
Email: brett@haydenir.com
|
|
|
|
www.haydenir.com
|
|
|
|
|
|
AIkido:
|
|
Phone: 212-745-1373
|
|
|
|
Email: investorrelations@AIkido.com
|
|
|
|
www.AIkido.com
|
|
|
|
|